FDA Health Alert: heart-surgery med Trasylol may increase the risk of death and stroke
September 30, 2006
On Friday, the Food and Drug Administration (FDA) announced that German pharmaceutical giant Bayer A.G., had failed to alert federal drug officials that their popular heart-surgery drug Trasylol, might increase the health risks of death and stroke. The drug company had known of those risks after learning the results of a large-scale study it conducted.
According to an article in the New York Times, Bayer scientists even attended a public meeting with the FDA in late September to discuss the drug's risks but did not mention the large-scale study conducted by the company with its very troubling results.
Another study, published in January in the New England Journal of Medicine, found that the Trasylol, which is given to patients before heart surgery, may increase the risks of kidney failure, heart attack and stroke.
see also:
Learn More
Side Effects of Trasylol Include Kidney Failure--Lawyers InvestigateTrasylol has been found to cause kidney problems--free legal review
Dextroamphetamine Sulfate
Drug company announces recall of ADHD drug Dextroamphetamine Sulfate Voluntary recall of Dextroamphetamine Sulfate drug used to treat ADHD
Drugs
What You Need to Know about the Link Between Gleevec and Heart FailureLink Between Gleevec and Heart Failure--New Precautions added to Label
